COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01349348
Recruitment Status : Completed
First Posted : May 6, 2011
Last Update Posted : October 12, 2012
Information provided by (Responsible Party):
Otsuka Beijing Research Institute

Brief Summary:
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.

Condition or disease Intervention/treatment Phase
Ascites Hepatic Cirrhosis Drug: Tolvaptan Drug: placebo Phase 3

Detailed Description:

For symptoms of fluid retention due to liver diseases (ascites and/or lower extremity edema, i.e. hepatic edema), treatment generally starts with bed rest and a low-salt diet. Aldosterone antagonists and loop diuretics are commonly used diuretics in the treatment of fluid retention due to liver diseases. In aldosterone antagonists' therapy, nevertheless, hyperkalemia is frequently reported, slow onset of action and dose escalation needed also impair its effect. If aldosterone antagonists' therapy is ineffective, loop diuretics as strong diuretics are usually added up. However, Dose escalation of loop diuretics also boost the occurrence of hyponatremia and hypokalemia, and combination of the two drugs provided fastest onset of effectiveness with less adverse events. While, because both diuretics can cause sodium lose which is difficult to prevent and treat, hyponatremia is easy to occur. The combination of aldosterone antagonists and K-sparing diuretics reduces the occurrence of hypokalemia but have little effect on the prevention and treatment of hyponatremia. In addition, there are still some patients who are resistent to loop diuretics or intolerant of an effective diuretic dosage due to adverse events.

Tolvaptan increases the excretion of electrolyte-free water (aquaretic) without changing electrolytes excretion by inhibiting the water reabsorption of collecting duct in kidney. It is demonstrated that Tolvaptan increased urine volume without impairing renal function.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 535 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blinded, Multicenter, Placebo Controlled, Parallel Designed Study, to Evaluate the Efficacy and Safety of Tolvaptan Tablet in Treatment of Patients With Cirrhosis Ascites, Using Diuretics as Initial Treatment
Study Start Date : October 2010
Actual Primary Completion Date : May 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
Drug Information available for: Tolvaptan

Arm Intervention/treatment
Experimental: Tolvaptan 15mg
Drug: Tolvaptan
tablet, 15 mg, Qd, for 7 days
Other Name: SAMSCA

Experimental: Tolvaptan 7.5mg
Drug: Tolvaptan
tablet, 7.5 mg, Qd, for 7 days
Other Name: SAMSCA

Placebo Comparator: Placebo
Tolvaptan 0mg/tab
Drug: placebo
tablet, 7.5/15mg , Qd, 7days.
Other Name: Blank tablet

Primary Outcome Measures :
  1. Change from baseline in body weight after 7 days randomized treatment (Day 8). [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. Change from baseline in body weight after 4 days randomized treatment (Day 5); [ Time Frame: 4days ]
  2. The rate of change from baseline in body weight after 4, 7 days randomized treatment (Day 5, Day 8); [ Time Frame: 4 and 7 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Patients diagnosed with liver cirrhosis clinically or pathologically;
  2. Patients with ascites confirmed by Type-B ultrasound scan after receiving combination therapies of oral loop diuretics and aldosterone antagonists for at least 4 days with the fixed usage and dosage
  3. Inpatients or patients who can be hospitalized for this study from Day -3 (Screening) to Day 8 (the day for efficacy evaluation);
  4. Patients with body weight change within ±1.0 kg in the 2 days prior to initiation of treatment (Day -2 and Day -1)
  5. Age: 18 to 75 years, inclusive(at the time informed consent is obtained);
  6. Genders: men or women;
  7. Patients who have signed informed consent form.

Exclusion criteria:

  1. Patients with any of the following diseases, complications or symptoms:

    • Hepatic encephalopathy (hepatic coma of grade II or higher1));
    • Malignant ascites (patients have tumor cells detected in ascites if malignant ascites be highly suspected);
    • Uncontrolled spontaneous bacterial peritonitis;
    • Patients who are likely to experience alimentary tract hemorrhage during the study;
    • Heart failure (NYHA2) grade III or IV);
    • Anuresis (daily urine volume is less than 100mL);
    • Dysuria due to urinary tract stricture, urinary calculus, tumor in the urinary tract or other cause.
  2. Patients with history of :

    • Alimentary tract hemorrhage within 10 days prior to screening;
    • Cerebral accident suffered within 30 days prior to screening;
    • Past history of hypersensitivity or idiosyncratic reaction to benzazepine derivatives (Benazepril).
  3. Patients with systolic pressure below 90mmHg at screening;
  4. Patients with any of the following abnormal laboratory parameters at screening:

    • Serum creatinine >1.5x upper limit of normal range;
    • Serum Na+>145mmol/L (or higher than upper limit of normal range);
    • Serum K+>5.5mmol/L;
  5. Patients with Child-pugh score3)>12;
  6. Patients who are unable to take medicine orally;
  7. Female patients who are pregnant, lactating, or who are at child-bearing age without using acceptable contraceptive means;
  8. Patients who received blood products including albumin within 4 days prior to the initiation of treatment
  9. Patients who participated in any clinical trial other than tolvaptan within one month prior to screening;
  10. Patients who participated in Tolvaptan trials and took Tolvaptan previously;
  11. Patients otherwise judged by the investigator, to be inappropriate for inclusion in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01349348

Layout table for location information
China, Shanghai
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai, China, 200001
Sponsors and Collaborators
Otsuka Beijing Research Institute
Layout table for investigator information
Principal Investigator: Minde Zeng RenJi Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Otsuka Beijing Research Institute Identifier: NCT01349348    
Other Study ID Numbers: 156-08-805-01
First Posted: May 6, 2011    Key Record Dates
Last Update Posted: October 12, 2012
Last Verified: October 2012
Keywords provided by Otsuka Beijing Research Institute:
Tolvaptan treatment to ascites and hepatic cirrhosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs